Tumor-targeted immune complex formation: Effects on myeloid cell activation and tumor-directed immune cell migration

International Journal of Cancer

Volumn 98, Issue 6, 2002, Pages 857-863

  Kroesen, Bart Jan ^a   McLaughlin, Pamela M J ^a   Schuilenga Hut, Petra H L ^b,c   Jacobs, Susan C ^a   Molema, Grietje ^a   Helfrich, Wijnand ^a   De Leij, Lou F M H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Epithelial glycoprotein 2; Fc receptor; Immune complex; Inflammation; Targeting

Indexed keywords

CD64 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPITHELIAL GLYCOPROTEIN 2; GAMMA INTERFERON; GLYCOPROTEIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERCELLULAR ADHESION MOLECULE 1; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZYMOSAN;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL INFILTRATION; CELL MIGRATION; COMPLEX FORMATION; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; OPSONIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE; CELL MOVEMENT; E-SELECTIN; HUMANS; IMMUNITY, CELLULAR; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; INTERLEUKIN-4; MICE; MYELOID CELLS; PLASMIDS; REACTIVE OXYGEN SPECIES; RECEPTORS, IGG; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037140116     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10245     Document Type: Article

References (43)

1. Immunologic approaches to the treatment of cancer
2. Renal cell carcinoma: Recent progress and future directions
3. Bispecific antibodies for treatment of cancer in experimental animal models and man
4. Immunology and immunotherapy of human cancer: Present concepts and clinical developments
5. Dendritic cells in cancer immunotherapy
6. Historical overview of biologic response modifiers
7. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma
8. Spontaneous remission of renal cell carcinoma: A case report and immunological correlates
9. Immunosuppression by human gangliosides: I. Relationship of carbohydrate structure to the inhibition of T cell responses
10. The host-tumor immune conflict: From immunosuppression to resistance and destruction
11. Where have all the T cells gone? Mechanisms of immune evasion by tumors
12. Renal cell carcinoma - Derived gangliosides suppress nuclear factor-kappaB activation in T cells
13. How much longer will tumour cells fool the immune system?
14. Tumor-induced immunosuppression: A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine
15. Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells?
16. Turning the immune system on
17. IgG receptor polymorphisms: Risk factors for disease
18. Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications
19. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1)
20. Clinical trials of antibody therapy
21. The therapeutic use of monoclonal antibodies in colorectal carcinoma
22. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma
23. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung
24. SCLC cluster 2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2
25. Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells
26. High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting
27. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
28. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes
29. Tumor necrosis factor alpha-induced endothelial tissue factor is located on the cell surface rather than in the subendothelial matrix
30. Chemiluminescence in activated human neutrophils: Role of buffers and scavengers
31. Suppressive effect of basic fibroblast growth factor on transendothelial emigration of CD4(+) T-lymphocyte
32. Analysis of in vitro lymphocyte adhesion and transendothelial migration by fluorescent-beads-based flow cytometric cell counting
33. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for anti-tumor efficacy
34. Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat model
35. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: Increased efficacy with multiple injections and CD28-induced costimulation
36. Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91)
37. Interferon-activated signal transduction to the nucleus
38. Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B and Sp1 transcription factors
39. Reactive oxygen intermediates enhance Fc gamma receptor signaling and amplify phagocytic capacity
40. FcgammaR expression on macrophages is related to severity and chronicity of synovial inflammation and cartilage destruction during experimental immune-complex-mediated arthritis (ICA)
41. Fc gamma receptor III induces actin polymerization in human neutrophils and primes phagocytosis mediated by Fc gamma receptor II
42. Role of the Fc gamma R subclasses Fc gamma RII and Fc gamma RIII in the activation of human neutrophils by low and high valency immune complexes
43. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89)